Treatment of chronic hepatitis C virus infection at the beginning of a new era

Česká verzia

Authors: P. Urbánek
Authors place of work: Interní klinika 1. lékařské fakulty UK a ÚVN Praha, přednosta prof. MU Dr. Miroslav Zavoral, Ph. D.
Published in the journal: Vnitř Lék 2013; 59(7): 612-617
Category:

Summary

After 2010 the therapy of chronic HCV infection entered a completely new era – the era that is marked with the gradual introduction of the so‑ called directly acting antivirals into treatment schemes of this serious disease. The term directly acting antivirals (DAA) covers low‑ molecular substances that inhibit viral non‑structural proteins – enzymes involved in the HCV replication cycle. At present, the first 2 representatives of DAA, Boceprevir and Telaprevir, have been approved for chronic HCV infection indication. The synoptic article pays the greatest attention to these 2 representatives, along with mentioning some other substances that are under later phases of clinical development and are likely to be approved in the near future.

Key words:
chronic hepatitis C – pegylated interferon – ribavirin – boceprevir – telaprevir

Zdroje

1. Ge D, Fellay J, Thompson AJ et al. Genetic variation in IL28B predicts hepatitis C treatment‑induced viral clearance. Nature 2009; 461: 399– 401.

2. Bacon BR, Gordon SC, Lawitz E et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1207– 1217.

3. Zeuzem S, Andreone P, Pol S. Telaprevir for retreatment of HCV infection. N Engl J Med 2011; 364: 2417– 2428.

4. Poordad F, McCone J Jr, Bacon BR et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1195– 1206.

5. Jacobson IM, McHutchison JG, Dusheiko G et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011; 364: 2405– 2416.

6. Sherman KE, Flamm SL, Afdhal NH et al. Response‑ guided telaprevir combination treatment for hepatitis C virus infection. N Engl J Med 2011; 365: 1014– 1024.

7. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol 2011; 55: 245– 264.

8. Ghany MG, Nelson DR, Strader DB et al. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology 2011; 54: 1433– 1444.

9. Urbánek P, Husa P, Galský J et al. Standardní diagnostický a terapeutický postup u chronické infekce virem hepatitidy C (HCV). Gastroent Hepatol 2012; 26: 214– 229.

10. Lalezari LP, Nelson DR, Hyland RH et al. Once daily sofosbuvir plus ribavirin for 12 and 24 weeks in treatment‑ naive patients with HCV infection: the QUANTUM study. Abstracts 48th Annual Meeting of the European Association for the Study of the Liver. Amsterdam 24.– 28. 4. 2013. Abstract 845.

11. Sulkowski MS, Gardiner DF, Rodroguez‑ Torres M et al. Sustained virologic response with daclatasvir plus sofosbuvir ± ribavirin (RBV) in chronic HCV genotype (GT) 1– infected patients who previously failed telaprevir (TVR) or boceprevir (BOC). Abstracts 48th Annual Meeting of the European Association for the Study of the Liver. Amsterdam 24.– 28. 4. 2013. Abstract 1417.

12. Kowdley KV, Lawitz E, Poordad F et al. Safety and efficacy of interferon‑free regimens of ABT‑ 450/ R, ABT‑ 267, ABT‑ 333 ± ribavirin in patients with chronic HCV GT1 infection: results from the AVIATOR study. Abstracts 48th Annual Meeting of the European Association for the Study of the Liver. Amsterdam 24.– 28. 4. 2013. Abstract 3.

13. Kowdley KV, Lawitz E, Poordad F et al. A 12‑week interferon‑free treatment regimen with ABT‑ 450/ r, ABT‑ 267, ABT‑ 333, and ribavirin achieves SVR12 rates (observed data) of 99% in treatment‑ naive patients and 93% in prior null responders with HCV genotype 1 infection. Abstracts 63rd Annual Meeting of the American Association for the Study of Liver Diseases. Boston 9.– 13. 11. 2012. Abstract LB‑ 1.